Cancer in Lebanon

IARC estimates 17,728 new cancer cases and 8,706 cancer deaths in Lebanon in 2024; the commonest new cancers are breast, trachea, bronchus and lung and bladder. This page is assembled automatically from OnCo's data: 16 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

17,728

all cancers

Deaths

8,706

all cancers

Incidence rate

242.2

per 100,000, age-standardised

Mortality rate

116.5

per 100,000, age-standardised

Cumulative risk

24.2%

of a cancer by age 74

Population

5,805,968

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	3,404	93.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	1,820	23.9	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Bladder	1,680	21.1	Bladder & urothelial cancer
Colorectum	1,644	21.6	Colorectal cancer
Prostate	1,411	38.5	Prostate cancer
Non-Hodgkin lymphoma	897	12.6	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Leukaemia	512	7.7	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Stomach	470	6.2	Gastric & gastro-oesophageal junction cancer
Thyroid	425	6.6	Thyroid cancer
Corpus uteri	375	9.5	Endometrial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,523	20.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	978	26.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	769	10.0	Colorectal cancer
Bladder	676	8.4	Bladder & urothelial cancer
Non-Hodgkin lymphoma	369	5.0	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Prostate	359	9.8	Prostate cancer
Stomach	351	4.6	Gastric & gastro-oesophageal junction cancer
Leukaemia	330	4.8	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Pancreas	305	4.0	Pancreatic ductal adenocarcinoma
Brain, central nervous system	262	4.0	Glioma & glioblastoma

Incidence: method 2a, national rates applied to the 2024 population.
Mortality: method 3c, national incidence estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Lebanon”, in Western Asia (Asia), High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

16 trials in OnCo · 1 recruiting overall

16 trials

Trial			Lead sponsor
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials NCT04064060	Phase 3	Recruiting	Celgene	143	2026-07-01
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798	Phase 3	Active not recruiting	Hoffmann-La Roche	198	2026-10-02
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer NCT04557059	Phase 3	Active not recruiting	Janssen Pharmaceutica N.V., Belgium	141	2026-09-25
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer NCT05132075	Phase 3	Active not recruiting	Novartis Pharmaceuticals	51	2026-09-25
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases NCT04603807	Phase 3	Active not recruiting	Hoffmann-La Roche	61	2026-08-13
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi NCT04717414	Phase 3	Active not recruiting	Celgene	185	2026-07-16
EMPOWER-Lung 1 NCT03088540	Phase 3	Completed	Regeneron Pharmaceuticals	192	2026-06-25
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555	Phase 3	Active not recruiting	Amgen	180	2026-01-12
CheckMate 227 NCT02477826	Phase 3	Completed	Bristol-Myers Squibb	290	2025-10-30
MONALEESA-2 NCT01958021	Phase 3	Completed	Novartis Pharmaceuticals	221	2025-03-07
SOLAR-1 NCT02437318	Phase 3	Completed	Novartis Pharmaceuticals	197	2025-02-13
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib NCT01828112	Phase 3	Completed	Novartis Pharmaceuticals	97	2025-02-07
ASCEND-4 NCT01828099	Phase 3	Completed	Novartis Pharmaceuticals	167	2025-01-16
GEOMETRY mono-1 NCT02414139	Phase 2	Completed	Novartis Pharmaceuticals	95	2024-03-20
ATLANTIS NCT02566993	Phase 3	Completed	PharmaMar	160	2021-10-28
10TASQ10 NCT01234311	Phase 3	Completed	Active Biotech AB	204	2015-10-21

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Lebanon, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Lebanon is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

American University of Beirut Medical Center / Naef K. Basile Cancer Institute

1 person

People whose main affiliation in OnCo is an institution or company in Lebanon.

Ali Taher

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Lebanon is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Lebanon's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Lebanon, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Lebanon's own sources.

Lebanon is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/lb.json; every country: /api/v1/countries.json.